Navigation Links
Ardea Biosciences Announces Exercise in Full of Overallotment Option for Common Stock Offering
Date:2/23/2011

ent, Jefferies & Company, Inc., 520 Madison Avenue, 12th Floor, New York, NY 10022, at 877-547-6340, or at Prospectus_Department@Jefferies.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Ardea Biosciences, Inc.

Ardea Biosciences, Inc., of San Diego, California, is a biotechnology company focused on the development of small-molecule therapeutics for the treatment of serious diseases.

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding Ardea's expectations with respect to the application of the net proceeds from the offering. Risks that contribute to the uncertain nature of the forward-looking statements include, among others, risks related to the outcome of preclinical and clinical studies, risks related to regulatory approvals, delays in commencement of preclinical and clinical studies, costs associated with Ardea's drug discovery and development programs, and risks related to the outcome of Ardea's business development activities, including collaboration or license agreements. These and other risks and uncertainties are described more fully under the headings "Risk Factors" in Ardea's most recently filed SEC documents, including its Annual Report on Form 10-K
'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Ardea Biosciences Prices Public Offering of Common Stock
2. Ardea Biosciences Announces Positive Top-Line Results from Phase 2b Combination Study of RDEA594 in Allopurinol-Refractory Gout Patients
3. Ardea Biosciences to Present at Two Upcoming Investor Conferences
4. Ardea Biosciences Awarded a $733,438 Grant from the U.S. Government Under the Patient Protection and Affordable Care Act
5. Ardea Biosciences to Present at the Oppenheimer 21st Annual Healthcare Conference
6. Ardea Biosciences Announces Appointment of Felix J. Baker, Ph.D. to Board of Directors
7. Ardea Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference
8. Cardea Technology Inc and Optasia Medical Ltd Announce Plans to Collaborate to Optimize Their Vertebral Fracture Assessment Tools
9. Ardea Biosciences to Present at the UBS Global Life Sciences Conference and the Third Annual JMP Securities Healthcare Focus Conference
10. Ardea Biosciences to Present Data on Gout and Inflammation Programs at the 2008 ACR/ARHP Annual Scientific Meeting
11. Ardea Biosciences to Present Data on Lead MEK inhibitor, RDEA119, at EORTC-NCI-AACR Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2015)... Texas , March 29, 2015 /PRNewswire/ ... presentation of important study data showing the ... in 1,599 gynecologic cancer samples. Using Caris ... profiling service, researchers identified expression of programmed ... cancers independent of histology while its ligand ...
(Date:3/27/2015)... YORK , 27. März 2015 /PRNewswire/ ... Prize in Biomedical Science für seine bahnbrechende ... Proteine zwischen Zellkompartimenten transportiert werden, sowie für ... Zellen zur Reaktion auf Stress nutzen, der ... Dr. Walter ist Professor für Biochemie an ...
(Date:3/27/2015)... Working in collaboration with the National Amyloidosis Centre at ... Richmond Pharmacology is the first centre worldwide to dose a ... RNAi therapeutic being developed for the treatment of transthyretin-mediated amyloidosis ... Read press release ClinicalTrials.gov ... University of London , Richmond Pharmacology is ...
(Date:3/26/2015)... WARREN, N.J., March 26, 2015  Roka Bioscience, ... company focused on providing advanced testing solutions for ... financial results for the three months and full ... Quarter 2014 Financial Results:Revenue for the quarter ended ... $689,000 for the fourth quarter of 2013 and ...
Breaking Biology Technology:Caris Life Sciences' Multiplatform Tumor Profiling Technology Identifies Expression of PD-1 and PD-L1 in Gynecologic Malignancies 2Caris Life Sciences' Multiplatform Tumor Profiling Technology Identifies Expression of PD-1 and PD-L1 in Gynecologic Malignancies 3Caris Life Sciences' Multiplatform Tumor Profiling Technology Identifies Expression of PD-1 and PD-L1 in Gynecologic Malignancies 4Deutschstämmiger Zellbiologe Peter Walter gewinnt den Vilcek Prize in Biomedical Science 2015 2Deutschstämmiger Zellbiologe Peter Walter gewinnt den Vilcek Prize in Biomedical Science 2015 3Deutschstämmiger Zellbiologe Peter Walter gewinnt den Vilcek Prize in Biomedical Science 2015 4Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 2Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 3Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 4Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 5Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 6Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 7
... , SADDLE RIVER, N.J., July 29 PDI, ... sales and marketing support to U.S. pharmaceutical companies, today announced that ... August 5, 2009 after the market close. , , ... at 4:30 p.m. Eastern time on August 5, 2009 to discuss ...
... RICHMOND, Calif., July 29 Sangamo BioSciences, Inc. (Nasdaq: ... and accomplishments. , , For the second ... of $4.5 million, or $0.11 per share, compared to a consolidated ... same period in 2008. As of June 30, 2009, the company ...
... , , , ... Corporation (Nasdaq: VRNM ) today announced that its ... Biofuels, and plan to relocate its corporate headquarters to Florida. ... the nation,s first commercial-scale cellulosic ethanol facilities, located in Highlands ...
Cached Biology Technology:PDI, Inc. to Hold Second Quarter 2009 Financial Results Conference Call on Wednesday, August 5, 2009 2Sangamo BioSciences Reports Second Quarter 2009 Financial Results 2Sangamo BioSciences Reports Second Quarter 2009 Financial Results 3Sangamo BioSciences Reports Second Quarter 2009 Financial Results 4Sangamo BioSciences Reports Second Quarter 2009 Financial Results 5Sangamo BioSciences Reports Second Quarter 2009 Financial Results 6Sangamo BioSciences Reports Second Quarter 2009 Financial Results 7BP and Verenium Announce Vercipia Biofuels to Advance the Commercialization of Cellulosic Ethanol 2BP and Verenium Announce Vercipia Biofuels to Advance the Commercialization of Cellulosic Ethanol 3BP and Verenium Announce Vercipia Biofuels to Advance the Commercialization of Cellulosic Ethanol 4
(Date:3/23/2015)... , Mar. 23, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... on the growing mobile commerce market, announces its biometric payment ... campaign on CNBC television starting March 30 th . ... airing in New York markets. ... "We are excited about our new ad campaign following the ...
(Date:3/20/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... on the growing mobile commerce market, announces its biometric ... the products featured in 2015 "I Want That" International ... EST on the DIY Network.   DIY,s ... , site of the 2015 International CES for ...
(Date:3/18/2015)... 18, 2015 As mobile payments become ... smart wallets and apps continue to be introduced into the ... the mobile payment industry in focus today are:  NXT-ID, Inc. ... BABA ), Apple Inc. (NASDAQ: AAPL ... Inc. (NASDAQ: FB ) NXT-ID, Inc. ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 2NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 3Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 2Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 3Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 4Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 5Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 6
... scans to measure blood flow in the lungs of people ... are most at risk of emphysema before the disease damages ... University of Iowa study. The study found that smokers ... normal lung function, have very different blood flow patterns in ...
... Chronix Biomedical today announced publication of a study ... tests to predict clinical status and monitor disease activity ... Chronix Biomedical uses proprietary technology to identify disease-specific genetic ... into the bloodstream by damaged and dying cells. ...
... 2010) -- A scientist at Barrow Neurological Institute in Phoenix ... Association (MDA) to continue his groundbreaking work in the disease ... part of MDA,s ongoing commitment to fund neuromuscular research that ... and related diseases. Including this funding, the MDA has ...
Cached Biology News:New test could identify smokers at risk of emphysema 2Chronix Biomedical's serum DNA assays monitor disease activity and treatment response in MS 2Chronix Biomedical's serum DNA assays monitor disease activity and treatment response in MS 3Barrow scientist receives $450K MDA grant 2
... The CHEMICON MDR1 Shift Assay provides a convenient ... occur upon transport of MDR1 substrates. Thus, the ... to which small molecules act as transport substrates ... in the presence of MDR1 substrates, the MDR1 ...
... Kit is a simple high performance method ... Removes detergents without significant dilution of protein ... on the Detergent-OUT Spin column and collect ... column is suitable for removing detergents from ...
... The wide and long ... of Polaroid gel documentation systems. ... holds the camera in place ... that allows photography on the ...
... microarrays are derived from Paraffin embedded tissue ... control procedures to ensure the highest quality. ... in one block, sectioned at a thickness ... slides. Sections are large (3-5 mm in ...
Biology Products: